Search hospitals > Pennsylvania > Beaver
UPMC-Heritage Valley Health System Beaver
Claim this profileBeaver, Pennsylvania 15009
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Squamous Cell Carcinoma
Conducts research for Non-Small Cell Lung Cancer
110 reported clinical trials
21 medical researchers
Summary
UPMC-Heritage Valley Health System Beaver is a medical facility located in Beaver, Pennsylvania. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Squamous Cell Carcinoma, Non-Small Cell Lung Cancer and other specialties. UPMC-Heritage Valley Health System Beaver is involved with conducting 110 clinical trials across 259 conditions. There are 21 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Melissa A. Burgess, and Dan P. Zandberg.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage II
Stage I
Stage III
Top PIs
Liza C. VillaruzUniversity of Pittsburgh Cancer Institute (UPCI)5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
37 reported clinical trials
53 drugs studied
Adam Brufsky, MDUniversity of Pittsburgh Cancer Institute (UPCI)1 year of reported clinical research
Expert in Breast Cancer
Studies Cancer
31 reported clinical trials
70 drugs studied
Melissa A. BurgessUniversity of Pittsburgh Cancer Institute (UPCI)4 years of reported clinical research
Expert in Sarcoma
Studies Soft Tissue Sarcoma
23 reported clinical trials
42 drugs studied
Dan P. ZandbergUniversity of Pittsburgh Cancer Institute (UPCI)1 year of reported clinical research
Expert in Cancer
Expert in Squamous Cell Carcinoma
18 reported clinical trials
33 drugs studied
Clinical Trials running at UPMC-Heritage Valley Health System Beaver
Breast Cancer
Prostate Cancer
Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Renal Cell Carcinoma
Oropharyngeal Carcinoma
Small Cell Lung Cancer
Laryngeal Cancer
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at UPMC-Heritage Valley Health System Beaver?
UPMC-Heritage Valley Health System Beaver is a medical facility located in Beaver, Pennsylvania. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Squamous Cell Carcinoma, Non-Small Cell Lung Cancer and other specialties. UPMC-Heritage Valley Health System Beaver is involved with conducting 110 clinical trials across 259 conditions. There are 21 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Melissa A. Burgess, and Dan P. Zandberg.